Objective: To examine the relationship between combination antiretroviral therapy (cART) and preterm delivery (PTD) or low delivery weight among pregnant Chinese women with HIV.
delivery weight in China. By expanding the evidence base to include populations that are more diverse, recommendations can be optimized regarding cART regimens for HIV-infected pregnant mothers in various low-income countries. The aim of the present study was to evaluate the effects of cART by regimen type and timing of treatment initiation on the risk of PTD and low delivery weight among pregnant Chinese women infected with HIV and their neonates.
| MATERIALS AND METHODS
The present retrospective cross-sectional study reviewed medical records pertaining to the perinatal period for all women with Patients were given one of these two regimens at the discretion of treating physicians on the basis of patient medical history, stage of HIV disease, and previous history of ART use, tolerance or resistance, as well as drug availability at the site.
Maternal demographic characteristics, timing of maternal HIV diagnosis and cART initiation, maternal obstetric history, prenatal course, results of clinical laboratory testing, neonate gender, delivery weight, delivery mode, delivery date, and pregnancy duration at delivery, were extracted from patient medical records. 
| RESULTS
During the 5-year study period, there were 748 singleton deliveries in the five study hospitals among 709 women who had HIV and were pregnant. Thirty-nine women had a second delivery during the study period. Seventeen women were excluded owing to incomplete maternal ART information (n=11), stillbirth (n=3), and maternal ART with three NRTIs (n=3); consequently, 731 mother-neonate pairs were included in the final analysis (Fig. 1) .
Overall, 559 (76.5%) mothers had cART exposure during pregnancy, and 172 (23.5%) did not. In the latter group, 12 (7.0%) received sd-NVP and 160 (93.0%) did not receive any treatment before delivery. Among the women exposed to cART during pregnancy, the numbers of women treated with a regimen containing EFV, NVP, or LPV/r were 104 (18.6%), 190 (34.0%), and 265 (47.4%), respectively ( Fig. 1 ).
In total, 10 neonates experienced vertical transmission of HIV; viral load was detected in nine neonates at delivery, and in one neonate during the follow-up period. The overall transmission rate was 1.4% (10 of 731 neonates).
Among the groups no significant differences were recorded in terms of maternal age, ethnicity, primiparous status, BMI before delivery, delivery mode, and gestational diabetes (Table 1) Table 1 ).
The median (IQR) pregnancy duration at delivery was 38 weeks In the univariate analysis (Table 2) , the early cART group had a nearly three-fold higher likelihood of PTD and a two-fold higher likelihood of low delivery weight compared with the no cART group.
No such effects were observed in the late cART group compared with the no cART group. Low maternal BMI (≤23.5) was associated with increased likelihood of low delivery compared with a BMI of 23.6-27.2. Female neonates exhibited a higher likelihood of low delivery weight compared with males (Table 2 ).
In the multivariate analysis (Table 2 ), the effect of early treatment remained significant with nearly three-fold higher odds of PTD and nearly two-fold higher odds of low delivery weight compared with the no-cART group. Similar results to the univariate analysis were also observed for low delivery weight among women with low BMI before delivery and female neonates. High maternal BMI (≥27.2) before delivery was associated with lower odds of low delivery weight compared with a BMI of 23.6-27.2 (Table 2 ).
In the subgroup analysis (Table 3) , early cART was associated with a higher likelihood of PTD compared with initiation of cART in the second or third trimester. A similar trend-higher likelihood among those in the early-cART group compared with the late-cART group-was demonstrated among women receiving cART with LPV/r and cART with, but this was not the case for patients who received F I G U R E 1 Flow chart of study population. Abbreviations: cART, combination antiretroviral therapy; EFV, efavirenz; LBW, low birthweight; LPV/r, lopinavir/ritonavir; NPV, nevirapine; NRTIs, nucleoside reverse transcriptase inhibitors; PTD, preterm delivery.
Neonates delivered by women with HIV at five hospitals in China, the EFV-based regimen. By contrast, neither regimen nor timing of cART initiation had a significant effect on the odds of low delivery weight (Table 3 ).
| DISCUSSION
In the present study, the overall incidences of PTD and low delivery weight were 12.7% and 18.2%, respectively. These rates are higher than the national averages reported as 7.0% for PTD 18 and 2.3% for low delivery weight.
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The present study reported on the association of prenatal cART with PTD and/or low delivery weight in a Chinese population. As compared with no perinatal cART, perinatal exposure to cART was associated with an increase in both PTD and low delivery weight.
These findings are similar to most studies from European 2-4,9 and African 13, 15, 17, 20 countries, but conflict with those from the USA and the Caribbean. [5] [6] [7] [8] [9] The effect was stronger among women who initiated cART before the pregnancy or in the first trimester. Only a few studies have evaluated the risk of adverse pregnancy outcomes associated with initiation of treatment earlier in pregnancy. 21 A meta-analysis of 14 studies in high-income countries 8 concluded that women starting cART pre-conception or in the first trimester had 1.71-fold higher odds of PTD as compared with those who initiated treatment in the second or third trimester. Subsequent to that meta-analysis, four more studies and two meta-analyses 3,7,12,16,22,23 examined this issue. The conclusions of the studies were similar, reporting a higher risk of PTD and sometimes low delivery weight when cART was initiated before as compared with after conception.
In the subgroup analysis, LPV/r-or NVP-based cART starting pre-pregnancy or in the first trimester was associated with a higher likelihood of PTD compared with initiating therapy later, but not low delivery weight. This analysis took into account the joint effects of cART regimen and the timing of treatment initiation on pregnancy outcomes. Although not consistent, similar findings have been previously reported. In a large USA-based surveillance cohort including 1869 mother-neonate pairs with HIV, premature delivery was significantly higher among mothers using protease inhibitor-based cART in the first trimester with an aOR of 1.55 (95% CI, 1.16-2.07; P=0.003), 7 which is similar to the magnitude of odds obtained in the present study.
There are limited and inconsistent reports on the association of prenatal NVP use and adverse pregnancy outcomes. 12, 15, 17 Those studies have varied in study design, population, and reference group, making a direct comparison with the present findings difficult. Further studies are needed to clarify any such associations.
Many women with HIV of childbearing age will face early exposure to cART, owing to either becoming pregnant while being treated with cART or starting cART immediately when found to be pregnant under T A B L E 1 (Continued) the "test and treat" strategy. Efforts should be made to optimize cART regimens, not only to reduce mother-to-child transmission but also to minimize adverse pregnancy outcomes. The findings of the present study suggest that EFV-based cART is preferable to other regimens for treatments that are started earlier in pregnancy.
Low maternal BMI (≤23.5) before delivery was independently associated with low delivery weight in the present study. Although different thresholds of BMI have been used to define underweight, the present findings are in line with most studies. 16, 24 They are also consistent with findings among women without HIV infection. 25 A study in the Côte women with HIV who received monotherapy for prevention of motherto-child transmission 24 showed that a BMI lower than 21.8 at delivery was associated with both PTD (OR, 1.82; 95% CI, 1.34-2.46) and low delivery weight (OR, 2.09; 95% CI, 1.41-3.08). The present study did not find an association between low BMI before delivery and PTD.
The present study had some limitations. First, it was a retrospective observational study; owing to the nature of the study design, the associations of cART with PTD and low delivery weight could be explored, but causality could not be inferred. Second, unmeasured bias could have been introduced in the earlier initiation of ART or in the choice of ART regimen, leading to confounding by indication.
Finally, some factors that have been previously reported to affect PTD, such as maternal illicit drug use, preterm delivery history, and maternal HIV viral load at delivery, were not examined because the data were unavailable or were not documented uniformly in the medical charts.
In conclusion, as compared with no prenatal cART, cART in pregnancy was found to be associated with both PTD and low delivery weight; however, this effect was present only among women who initiated cART before pregnancy or in the first trimester of pregnancy.
For women who recevied prenatal cART, those who received LPV/rand NVP-based cART and started the treatment before conception or in the first trimester had a higher likelihood of PTD, but not low delivery weight. Malnutrition with low maternal BMI before delivery was found to be an independent risk factor for low delivery weight.
Even though the benefits of cART for pregnant women with HIV in decreasing mother-to-child transmission of HIV are well documented, the present findings suggest that EFV-based regimens could be favorable to avoid PTD or low delivery weight, at least in the Chinese population, and particularly if exposure occurs before pregnancy or in the first trimester of pregnancy. Improving the nutritional status of women with HIV who are pregnant could also help to reduce the risk of low delivery weight.
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